R3t@trutide 32 mg Self-Mix | Health Tech
Certificate of Analysis (COA) View the laboratory certificate for this product [ View COA ]

Noventra R3t@trutide 32 mg Self-Mix

R 1,550.00 R 1,540.00
Add to WishlistCompare

Noventra Pharma Retatrutide 32 mg — Multi-Dose Ampule

Product Description

Explore the science behind next-generation metabolic research with Noventra Pharma Retatrutide 32 mg, a multi-dose ampule presented in a pharmaceutical-style research format.

Retatrutide is an investigational triple-hormone receptor agonist designed to activate three pathways involved in metabolic regulation: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.

This triple-receptor activity has made retatrutide a significant subject of clinical research into body-weight regulation, glucose metabolism, and cardiometabolic health.

Product Specifications

  • Brand: Noventra Pharma

  • Compound: Retatrutide

  • Labelled strength: 32 mg

  • Format: Multi-dose ampule

  • Presentation: 1 × 32 mg ampule

  • Additional item shown on packaging: 1 × 2 ml bacteriostatic water ampule

  • Research category: Metabolic and incretin-pathway research

Key Research Areas

  • Body-weight regulation: Investigated for its potential effects on body weight and energy balance.

  • Appetite-related pathways: Studied through GLP-1 and GIP receptor signalling.

  • Glucose metabolism: Investigated for effects on glycaemic markers and insulin-related measures.

  • Cardiometabolic markers: Clinical research has examined changes in waist circumference, blood pressure, and blood lipid measurements.

  • Triple-receptor activity: Combines GIP, GLP-1, and glucagon receptor agonism in a single investigational molecule.

Key Features
  • Retatrutide, listed as R3t@trutide
  • 32 mg listed quantity
  • Self-mix format
  • Supplier: Noventra
Dosage & Usage

Week 1: 1.5 mg

Week 2: 3.0 mg

Week 3: 4.5 mg

Week 4: 6.0 mg

Week 5: 7.5 mg

Week 6: 9.0 mg

Week 7: 10.5 mg

Week 8: 12.0 mg

FAQ's & Tips

What product is listed here?

This listing is for Noventra Retatrutide, also written as R3t@trutide, in a self-mix, multi-dose ampule format.

What does the 32 mg label mean?

32 mg is the labelled amount for the ampule in this listing. It is not an individual dose or a dosing recommendation.

What presentation is described?

The product description lists one 32 mg ampule and notes that a 2 ml bacteriostatic water ampule is shown on the packaging. Confirm the supplied contents with Health Tech before ordering if you need clarification.

Where can I find research information?

The Research section provides links to registered studies about retatrutide. These references concern the compound and do not establish the safety, purity, effectiveness or suitability of this specific product.

Does this FAQ provide mixing or dosing instructions?

No. This FAQ explains the listing only and does not provide preparation, administration or treatment guidance.

Research

R3t@trutide (LY3437943) is being studied in clinical trials. The references below provide research context about the compound; they do not establish the safety, purity, effectiveness or suitability of this specific product.

Obesity and overweight research: NCT07232719 — A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight. This Phase 3 study is listed as active, not recruiting.

Weight-reduction maintenance research: NCT06859268 — A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity. This Phase 3 study is listed as active, not recruiting.

Drug-interaction research: NCT06808802 — Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants. This Phase 1 study is listed as completed. A completed study status alone does not establish a positive result.

Study status checked on 16 October 2026. Trial registration does not mean a treatment is approved or that results are available. These links are for research information, not mixing, dosing or treatment guidance.

Reviews